Histone deacetylase (HDAC)6 is a member of the class IIb HDAC family. This enzyme is zinc-dependent and mainly localized in the cytoplasm. HDAC6 is a unique isoenzyme with two functional catalytic domains and specific physiological roles. Indeed, HDAC6 deacetylates various substrates including α-tubulin and HSP90α, and is involved in protein trafficking and degradation, cell shape and migration. Consequently, deregulation of HDAC6 activity was associated to a variety of diseases including cancer, neurodegenerative diseases and pathological autoimmune response. Therefore, HDAC6 represents an interesting potential therapeutic target. In this review, we discuss structural features of this histone deacetylase, regulation of its expression and activity, biological functions, implication in human disease initiation and progression. Finally will describe novel and selective HDAC6 inhibitors.
Acetylation of the ε nitrogen of lysine residues is catalyzed by histone acetyltransferases (HATs). Deacetylation of both nuclear proteins (including histones) and cytoplasmic proteins is catalyzed by histone deacetylases (HDACs).
In mammals, HATs are classified into two groups according to their cellular localization: group A is primarily nuclear, whereas group B is essentially cytoplasmic. A classification system using their sequence similarities is compromised by the lack of similarity between these enzymes. However, selected enzymes are classified according to their sequence similarity and function into the following families: GNAT (general control [GC] N5 related N-acetyltransferase), p300/CBP (cAMP response element-binding protein [CREB]-binding protein), MYST (MOZ, Ybf2/Sas3, SAS2 and TIP60), TAFII250 (TBP [TATA box binding protein]-associated factor 250 kDa) and steroid receptor cofactor (SRC) (for review, see [1] ). All HAT enzymes use acetyl-coenzyme A as a cofactor.
There are 18 mammalian HDACs subdivided into four classes based on their sequence identity and catalytic activity (Figure 1 ). Indeed, classes I, II and IV are enzymes with a zinc ion at the bottom of their catalytic pocket essential for the deacetylation reaction; class III enzymes do not possess this ion, but their activity depends on the cofactor nicotinamide adenine dinucleotide (NAD + ). Class I includes HDAC1, 2, 3 and 8, which are located mainly in the nucleus due to the presence of a nuclear localization signal (NLS). Interestingly, HDAC3 possesses also a nuclear export signal (NES) in the catalytic domain. Class II is divided into two subclasses: subclass IIa including HDAC4, 5, 7 and 9 and subclass IIb consisting of HDAC6 and 10. Class II isoenzymes possess a NLS as well as a NES except HDAC9 (NLS only) and HDAC10 (NES only). Class IV corresponds to HDAC11. Class III, also known as sirtuins by analogy with yeast silent information regulator 2 (SIR2), contains seven members, SIRT1 to 7; some members contain NES and/or NLS (for review, see [2] 
HDAC6
Protein structure HDAC6 is the only isoenzyme of the HDAC family with two functional active sites. This enzyme presents specific protein domains (from N-terminal to C-terminal): a NLS rich in arginine and lysine sequences; a leucine-rich NES; catalytic sites 1 and 2; a cytoplasmic retention signal called SE14, which is a repeated sequence of eight consecutive Ser-Glu tetradecapeptides is present in human but absent in mouse, Drosophila and Caenorhabditis elegans and a zinc finger ubiquitin binding domain (BUZ, Figure 1 ) (for review, see [3] [4] [5] ). HDAC6 activity is regulated by posttranslational modifications: kinases such as Aurora A, extracellular signal-regulated kinase (ERK), glycogen synthase kinase 3β (GSK), G protein-coupled receptor kinase 2 (GRK), protein kinase C α (PKC), epidermal growth factor receptor (EGFR) or casein kinase 2 (CK) phosphorylate HDAC6 on threonines (T868, T30, T1031), serines (S22, S458, S846, S847, S1035 and S1062) and tyrosine Y570 leading to increased deacetylase activity [6, 7] . In addition, various lysines HDAC6 is mainly localized in the nucleus of undifferentiated cells, such as embryonic stem cells, neuronal cells and some cancer stem cell lines. In the nucleus, HDAC6 regulates TIP60-p400 and relocalizes into the cytoplasm during differentiation [11] . The NES sequence of HDAC6 contributes to its cytoplasmic localization which is chromosome region maintenance (CRM)1-dependent. Inhibition of cell proliferation or CRM1 activity triggers HDAC6 nuclear relocalization [12] . Moreover, the cytoplasmic retention of HDAC6 is controlled by repeated SE14 by a mechanism that remains to be elucidated [4] . Finally, acetylation at the NLS by p300 inhibits the interaction of HDAC6 with importin-α, resulting in its cytoplasmic retention [10] .
Regulation of HDAC6 expression
The gene encoding HDAC6 is located on chromosome X p11.22-23 and covers 21923 base pairs. HDAC6 is essentially expressed in kidney, liver, heart and pancreas [13] . Its promoter contains neither a TATA box nor a CCAAT box, but includes a 1-kb CpG island. Within the promoter, binding sites for NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and the glucocorticoid receptor were identified [14] . Transcription of this gene results in a 3648-bp mRNA with 28 exons [13] . HDAC6 expression depends on the methylation status of its promoter. For instance, compared with healthy controls, promoter hypomethylation, which is commonly associated to a more relaxed chromatin state and transcriptionally active genes, correlates with HDAC6 overexpression in patients with chronic obstructive pulmonary disease [15] .
HDAC6 may undergo alternative splicing resulting in a truncated protein, called p114, in which the N-terminal region contains both NES and NLS sequences. This truncated isoform still deacetylates α-tubulin. In addition, p114 is required for the expression of the epithelial-mesenchymal transition marker E-cadherin in transforming growth factor (TGF)-β1-treated A549 cells [16] .
Expression of HDAC6 is also regulated by microRNAs (miR) such as miR-548, miR-22 and miR-433. For example, in B-cell lymphomas, the decreased expression of miR-548 targeting the 3'-untranslated region (3'-UTR) of HDAC6 induces its overexpression. The authors showed that the adhesion of lymphoma cells to stromal bone marrow or lymph nodes triggers c-myc expression, which is involved in the repression of miR-548 promoter. Accordingly, HDAC6 overexpression in these cells induces the degradation of the pro-apoptotic protein Bim and is associated with increased cell growth and survival [17] . Regulation of HDAC6 by miR-22 favors the differentiation of mesenchymal stem cells into osteoblasts at the expense of adipogenesis [18] . Finally, in the case of X-linked chondrodysplasia, a mutation in the 3'-UTR of the HDAC6 mRNA induces a modification of the recognition site of miR-433 leading to HDAC6 overexpression [19] .
Physiological roles of HDAC6
Cytoskeleton structure & dynamism As witnessed by both cytoplasmic presence and retention of HDAC6, this enzyme clearly plays a crucial role in maintaining cellular shape and polarity, intracellular transport, division, migration, directional movement of the cells and angiogenesis (for review, see [3] ). These mechanisms are mainly under the control of cytoskeletal dynamics. This network consists of microtubules (α-and β-tubulin polymers), intermediate filaments (consisting of fibrillar proteins) and filamentous actins (F-actin polymers of globular or G-actin).
α-tubulin is acetylated at lysine 40 by α-tubulin acetyltransferases (αTAT) including ELP3 (elongator complex protein 3), ARD1 (arrest-defective-1 protein), NAT10 (N-acetyltransferase 10) or GCN5 (general control nonderepressible, Figure 2 ) [20] [21] [22] [23] . Its deacetylation by HDAC6 and SIRT2 is associated with depolymerized microtubules ( Figure 3A ) [24, 25] . Actin polymerization and crosslinking is facilitated by cortactin (Figure 2 ). This protein is acetylated on lysines within its F-actin-binding repeats by acetyltransferase p300/CBP-associated factor (PCAF). HDAC6 and SIRT1 deacetylate cortactin which then binds to F-actin and enhances polymerization ( Figure 3A ) [26, 27] .
In addition, microtubules are important for addressing misfolded proteins to the microtubule-organizing center (MTOC) for proteasome-independent degradation [3, 24, 28] . It has been shown that HDAC6 is involved in this mechanism, independently of its deacetylase activity ( Figure 3B ). Indeed, after inhibition of the proteasome, the cell must be able to protect itself against accumulating misfolded proteins. HDAC6 interacts with polyubiquitinated proteins and dynein motor protein, via its ubiquitin-binding domain [29] . The retrograde transport of these complexes will be possible toward the MTOC and HDAC6 participates in this elimination of misfolded proteins. Then, at the MTOC, aggresomes are formed around misfolded proteins due to deacetylation of cortactin by HDAC6. Aggresomes fuse with autophagosomes and lysosomes to degrade proteins [28] . In addition, formation and removal of aggresomes is regulated by phosphorylation of ser-future science group Review Seidel, Schnekenburger, Dicato & Diederich ine 458 of HDAC6 by casein kinase (CK)2, which increases its deacetylase activity [30] . Furthermore, deacetylated cortactin interacts with F-actin, triggering intense polymerization associated with increased cell migration as well as regulation of autophagosome fusion with lysosomes [26, 28] . HDAC6 also regulates autophagic degradation by deacetylating LC3B-II (microtubule-associated protein 1 light chain 3), a key regulator of autophagy, concomitant with degradation of p62/SQSTM (sequestrome)1. It is unknown if LC3B-II is deacetylated before or during fusion of the autophagosome with the lysosome [31] . HDAC6 is involved in autophagy by deacetylation of autophagyrelated proteins as well as through an adaptor role in a deacetylase-independent manner.
Proteasomal degradation
HDAC6 regulates proteasome-dependent protein degradation (for review, see [3] ). Chaperone heat shock protein (HSP)90α is a HDAC6 substrate that, upon deacetylation, interacts with client proteins including Bcr-Abl (breakpoint cluster region, V-Abl Abelson murine leukemia viral oncogene homolog 1), the glucocorticoid receptor (GR) or the androgen receptor (AR), thus ensuring that these protein maintain a favorable conformation to allow physiological activities [32] [33] [34] . Cortactin is acetylated by p300 and PCAF, whereas α-tubulin is acetylated by different enzymes carrying functional activity, such as α-tubulin acetyltransferase elongator protein 3, arrest-defective-1 protein, N-acetyltransferase 10, general control nonderepressible or Mec17. These two proteins are deacetylated by HDAC6; cortactin is deacetylated by SIRT1 and α-tubulin is deacetylated by SIRT2. The deacetylation of cortactin leads to its association with F-actin, and the deacetylation of α-tubulin induces an increase in microtubule dynamics, allowing mobility and cell division. Ac: Acetyl; PCAF: P300/CBP-associated factor; HDAC: Histone deacetylase; SIRT: Sirtuin. Acetylation of HSP90α induces a loss of its chaperone activity and therefore degradation of its client proteins ( Figure 3C ). HSP90α also interacts with heat shock factor (HSF)1, in a complex with chaperone valosin-containing protein/ATPase (VCP/p97) and maintains it in an inactive form [35] . An accumulation of misfolded proteins causing the dissociation of the complex with the release of HSF1 which will activate transcription of various HSPs and the release of HDAC6, which will bind to polyubiquitinated proteins. The ability of HDAC6 to bind ubiquitin is involved in the elimination of damaged and polyubiquitinated mitochondria. HDAC6, together with the ubiquitin-binding protein p62/SQSTM1, then form mito-aggresomes that will be eliminated by mitophagy [36] . In addition, HDAC6 targets and deacetylates GRP78 (78 kDa glucose-regulated protein) involved in unfolded protein response (UPR). Acetylation of GRP78 leads to its dissociation with PERK (protein kinase RNA-like ER kinase) resulting in activation of UPR followed by cell death [37] .
Endocytosis & exocytosis
HDAC6 participates in the regulation of exocytosis and endocytosis vesicles. For example, the EGFR receptor, when bound to its ligand, interacts and inactivates HDAC6 by phosphorylation, which leads to microtubule hyperacetylation and receptor internalization [38] . HDAC6 is also involved in the formation and internalization of macropinosomes, in the remodeling of actin and the formation of membrane ruffles. However, the induction of these processes as well as cell motility requires not only HDAC6 activity but also HSP90α and Ras-related C3 botulinum toxin substrate (Rac)1. Upon stimulation of cells by growth factors, these three proteins co-localize at membrane ruffles, where their activity is required [39] .
Apoptosis
HDAC6 is also involved in the regulation of apoptosis ( Figure 3D ). The acetylation status of cytoplasmic Ku70 is controlled by HDAC6 and controls its interaction with the proapoptotic BAX (Bcl-2-associated X protein) protein. When Ku70 is acetylated, it no longer interacts with BAX, which then activates apoptosis. In contrast, deacetylation of Ku70 by HDAC6 causes BAX sequestration and thereby the inhibition of apoptosis [40] . In addition, acetylated Ku70 dissociates from the antiapoptotic protein FLIP (FLICE [FADD-like IL-1 β-converting enzyme] inhibitory protein) leading to its proteasomal degradation and induction of apoptosis [41] . HDAC6 is also involved in PI3K (phosphoinositide 3-kinase)/AKT and mitogenactivated protein kinase (MAPK)/ERK signaling pathways ( Figure 3E ) [42] . Indeed, HDAC6 knockdown or HDAC6 catalytic inhibition promote AKT and ERK dephosphorylation associated with reduced cell proliferation and an induction of cancer cell death. Indeed, HDAC6 inhibition disrupts its interaction with protein phosphatase 1 that could dephosphorylate its targets phospho-AKT and phospho-ERK. Moreover, HDAC6 inhibition triggers HSP90 hyperacetylation leading to a decrease of phosphorylated AKT and ERK levels [43] [44] [45] [46] .
Other mechanisms Antioxidant activity
The antioxidant enzymes peroxiredoxin (Prx) 1 and 2 are substrates of HDAC6. The inhibition of HDAC6 induces increased acetylation of these Prx associated with enhanced activity, which may induce reduction of cancer cell resistance to chemotherapy [47] .
Transcriptional repression
As mentioned above, HDAC6 can be localized in the nucleus ( Figure 3F ), where it contributes to transcriptional repression through interaction with different co-repressors such as SUMOylated p300 or HDAC11 [48, 49] . Moreover, Runx2 (Runt-related transcription factor) recruits HDAC6 from the cytoplasm to chromatin in osteoblasts in order to repress the p21 promoter [50] . In addition, HDAC6 interacts with LCoR (ligand-dependent nuclear receptor co-repressor) and increases its repression activity. In MCF-7 cells, LCoR and HDAC6 are recruited to promoters of estrogen receptor (ER)α target genes in response to estrogen [51] .
Role of HDAC6 in diseases
HDAC6: tumor inducer or suppressor?
Alterations of DNA methylation, histone modifications or miRNA expression changes are epigenetic hallmarks of cancer (for review, see [52] [53] [54] ). In cancer, a pathological deregulation of these mechanisms occurs by overexpression or mutation of key epigenetic mechanisms. Due to the reversible nature of epigenetic modifications, small molecules able to modulate factors involved in epigenetic regulation have gained considerable interest. Recently, HDAC and HAT modulators were identified from natural sources and their anticancer properties were characterized. Accordingly, several studies showed promising results with these regulators that could be used as therapeutic agents. Furthermore, since epigenetic alterations are detected early during tumorigenesis and are potentially imitating events of tumor development, epigenetic modulators may open up new therapeutic opportunities for the development of chemopreventive approaches against cancer (for review, see [52, 53, 55] ). Among epi-future science group
Histone deacetylase 6 in health & disease Review genetic modulators, only four chromatin-modifying agents are approved so far for anticancer therapy: two DNA demethylating agents and two deacetylase inhibitors. Nevertheless, the combination of 'classical' anticancer agents with epigenetic modulators appears to be a promising future strategy against cancer (for review, see [54] ). In addition, HDAC6 expression is upor downregulated in several cancer subtypes (Table 1) .
For example, its overexpression in acute lymphoblastic leukemia (ALL), hepatocellular carcinoma and ovarian cancer is increased in advanced stages of these diseases. Intriguingly, increased HDAC6 expression in chronic lymphocytic leukemia (CLL) and cutaneous T-cell lymphomas (CTCL) is associated to longer survival. In the following parts of this review, we will describe HDAC6 alterations in cancer and its role as an oncogene or tumor suppressor.
Role of HDAC6 as an oncogene HDAC6 overexpression in cancer cells contributes to cancer development by modifying the acetylation status of many target proteins. Indeed, HDAC6 overexpression is correlated with a more advanced tumor stage and increased tumor aggressiveness and therefore a lower survival rate in oral squamous cell carcinoma, acute myeloid leukemia (AML), ovarian cancer and hepatocellular carcinomas [56] [57] [58] . In ovarian cancer, ubiquitin proteasome system (UPS) stress is compensated by HDAC6-mediated protein degradation via lysosomal pathways, thus inducing resistance against cell death [56] . Remarkably, HDAC6 overexpression in hepatocellular carcinoma cells accelerates the migration and invasiveness of tumor cells [58] . Furthermore, it was shown in various models, including ovarian and breast cancer cell lines, that HDAC6 overexpression may be due to oncogenic Ras signaling causing substrate-independent proliferation of cancer cells [42] .
Role of HDAC6 as a tumor suppressor
Surprisingly, HDAC6 may also play a role as a tumor suppressor. This is particularly the case in CLL, CTCL, hepatocellular carcinoma, pulmonary carcinoma and non-small-cell lung cancer (NSCLC). Indeed, overexpression of HDAC6 in CLL or CTCL is correlated to longer survival without treatment and a better prognosis [59] [60] [61] . In addition, Jung et al. described decreased HDAC6 expression in hepatocellular carcinoma associated with poor prognosis. Loss of HDAC6 activity decreases autophagy, and the ectopic expression of this enzyme restores cell death via activation of autophagic mechanisms [59] .
Dual HDAC6 activity in breast cancer
In breast cancer, ER regulates HDAC6 expression. HDAC6 overexpression in breast cancer is correlated to a better prognosis and response to endocrine treatment. For example, overexpression of HDAC6 correlates to smaller tumors with reduced histological cancer markers. Estrogen and progesterone receptor-positive tumors show a better response to tamoxifen treatment, increasing patient survival [62] . Furthermore, HDAC6 overexpression in ER-positive cells refractory to endocrine therapy is associated with poor prognosis. In addition, association of HDAC6 overexpression with another ER target, insulin-like growth factor-binding protein 4 (IGFBP4), further decreases vital prognosis. The authors suggest studying the expression level of ER target genes to personalize treatment of patients with ER-positive breast tumors [63] .
Other studies demonstrated that HDAC6 overexpression is correlated with increased mobility, migration and invasiveness of tumor cells. A comparison of the MDA-MB-231 and MCF-7 breast cancer cell lines revealed the important role played by HDAC6 in invasion. MDA-MB-231 cells show increased invasiveness ALL Overexpressed -expression increased in advanced stage [57] AML Overexpressed [57] Breast Overexpressed -correlated with better or poor prognosis [62, 63] CLL Overexpressed -correlated with longer survival [61] CTCL Overexpressed -correlated with longer survival [60] Hepatocellular carcinoma Overexpressed -expression increased in advanced stage -Under expressed [14, 58] Oral squamous cell carcinoma Overexpressed -expression increased in advanced stage [109] Ovarian Overexpressed -expression increased in advanced stage [56] Urothelial cancer Overexpressed [110] ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; CLL: Chronic lymphocytic leukemia; CTCL: Cutaneous T-cell lymphoma.
future science group Review Seidel, Schnekenburger, Dicato & Diederich compared with MCF-7 cells, and they overexpress HDAC6 as well as matrix metalloproteinase (MMP)9 [64] . Altogether these findings point out that HDAC6 expression may serve as a new cancer biomarker for diagnosis, tumor staging or prognosis leading to improved disease-free survival and better response to endocrinebased therapy. In the future, personalized drug therapies could be based on HDAC6 expression levels.
HDAC6: harmful or protective role in neurodegenerative diseases?
A common feature of neurodegenerative diseases (ND) is the presence of protein aggregates. Since UPS is altered in ND, autophagy was described to compensate misfolded protein degradation. As described above, HDAC6 plays an important role in the elimination of misfolded proteins or tagged for degradation and represents an interesting link between UPS and autophagy ([65] and for review, see [66] ).
Negative effect of HDAC6 in Alzheimer's disease
Alzheimer's disease is characterized by the extracellular accumulation of β-amyloid peptide and the intracellular accumulation of the protein tau (tubule-associated unit) [67, 68] . Hyperphosphorylation of tau decreases its affinity for microtubules, which leads to cytoskeleton disorganization, especially in neuronal cells, eventually leading to apoptotic cell death. Tubule-associated unit (Tau) is a client of HSP90α and deacetylation of this chaperone by HDAC6 contributes to maintenance of physiological folding of selected client proteins. β-amyloid peptide affects microtubules and consequently signaling pathways and intracellular vesicular transport. These alterations lead to a deterioration of the traffic of mitochondria and neurotransmitters resulting in synapse degradation. Furthermore, HDAC6 inhibition leads to hyperacetylated α-tubulin and restores mitochondrial transport. Accordingly, HDAC6 inhibition, leading to a degradation of tau and the restoration of β-amyloid-induced damages, could become an attractive novel therapeutic approach against Alzheimer's disease [69, 70] .
Protective role of HDAC6 in Parkinson's & Huntington's diseases
Parkinson's disease is a genetic and hereditary disease characterized by a disorder of the dopaminergic system and the presence of Lewy bodies composed of α-synuclein [71] . Accumulation of insoluble α-synuclein is toxic. In Drosophila models of Parkinson's disease, HDAC6 was reported to promote inclusion formation, which leads to the elimination of aggregates, therefore this enzyme is considered to have a protective role [72] .
Huntington's disease is also characterized by neuronal atrophy and accumulation of toxic huntingtin aggregates. These aggregates could be degraded by autophagic mechanisms through their addressing by HDAC6 to aggresome. Therefore, HDAC6 may play a protective role in Huntington's disease [73] . However, another study suggests that HDAC6 inhibition could be beneficial for Huntington's disease since microtubule-based transport is altered in this disease and HDAC6 plays a crucial role in tubulin network [74] . Surprisingly, HDAC6 knockout in a mouse model for Huntington's disease do not modify disease progression despite increased tubulin acetylation [75] .
Role of HDAC6 in other diseases

Autoimmune diseases Immunosuppressive effects of HDAC6 inhibition
In response to virus and bacteria infection, T cells are activated and differentiate into specialized and functional effector T cells. In order to control this mechanism, regulator T cells (Tregs) suppress effector T cell activation and function to prevent excessive or self-destructive immune response [76] . Foxp3 (Forkhead box p3) is a key transcription factor involved in the development and function of Tregs under the control of HDAC6 [77] . Indeed, HDAC6 knockout or HDAC6 inhibitor (HDAC6i) treatments suppress Treg function. Interestingly, HSP90 inhibitors lead to similar results suggesting that enhancement of Treg function followed by HDAC6 inhibition is HSP90-dependent [78] . In addition, it was shown that HDAC6 translocates into the nucleus after Treg activation, where it deacetylates Foxp3. Surprisingly, HDAC6 knockdown induces Foxp3 hyperacetylation leading to its proteasomal degradation [79] . Increased suppressive function of Tregs via HDAC6 inhibition is an important target in autoimmune disorders as well as inhibition of allograft rejection ([80] and for review, see [81] ).
Among autoimmune diseases, rheumatoid arthritis (RA) is a chronic autoimmune and inflammatory disease. Signal transduction regulators and transcription factors involved in the regulation of immune response and inflammation are well known substrates of HDACs. Therefore, it appears interesting to target HDACs to fight RA [82] . Surprisingly, treatment by the potent class I HDAC inhibitor largazole induces HDAC6 expression in synovial fibroblasts in RA. Cotreatment of largazole and the HDAC6i tubastatin decreases intracellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 expression induced by tumor necrosis factor (TNF)α and inhibits MMP-2 activity [83] . Studies using mouse models of inflammation showed that treatment with future science group Histone deacetylase 6 in health & disease Review tubastatin induces α-tubulin acetylation, inhibition of IL-6 and decreases inflamed paw volume. Authors conclude that HDAC6i possess anti-inflammatory and antirheumatic effects [84] .
Role of HDAC6 against HIV infection
The first steps of HIV-1 infection require interaction between the viral glycoprotein (gp)120 with a cell surface receptor such as cluster of differentiation (CD)4, C-C chemokine receptor type 5 (CCR5) and C-X-C chemokine receptor type 4 (CXCR4) leading to membrane fusion [85] . Interestingly, HDAC6 overexpression prevents virus-cell fusion and infection through regulation of microtubule dynamics by deacetylating α-tubulin. In contrast, HDAC6 knockdown or inhibition of its deacetylase activity induces HIV-1 infection and syncytia formation [86] . After reverse transcription and integration of the virus genome, transcription of viral genes leads to replication. Tat protein is essential for HIV-1 transcription as it binds HIV transactivation response element (TAR) with cyclin T1 allowing the recruitment of cyclin-dependent kinase (Cdk)9, which phosphorylates the C-terminal part of RNA polymerase II leading to increased elongation efficacy [87, 88] . Tat activity is regulated by acetylation of two lysines: K28, acetylated by p300/PCAF and deacetylated by HDAC6, and K50, acetylated by p300 and Gcn5 and deacetylated by SIRT1, 2 and 3 [89] . It has been reported that acetylation of K28 enhances elongation, whereas acetylation of K50 has the opposite effect. Finally, HDAC6 inhibition leads to increased interaction between Tat and cyclin T1 and therefore increases Tat activity. In consequence, HDAC6 plays a crucial role in HIV infection.
Role of HDAC6 in virus or bacteria response
During virus and bacteria infection, host organisms activate several pathways in order to fight infection. Among these, activation of T cells by antigen presenting cells (APCs) is required for elimination of infected cells or bacteria [90] . In APCs, HDAC11 represses IL-10 expression, whereas HDAC6 induces its expression, which is important for the activation of T cells [91] . When T cells interact with APCs, a rearrangement of actin filaments as well as microtubules is required for the formation of supramolecular activation clusters (SMACs), antigen receptor redistribution and T cell adhesion to the contact site, called the immune synapse. In T cells, HDAC6 contributes to immunological synapse organization as both microtubules and deacetylase concentrate at the contact site. Here co-stimulator and adhesion receptor distribution is disorganized in HDAC6 overexpressing cells. Altogether, HDAC6 plays an important role in immune synapse organization as well as in T cell activation after infection [92] .
Virus infection causes cellular stress leading to formation of stress granules (SGs). SGs contain untranslated mRNAs in order to protect them against damage and increase expression of stress proteins. HDAC6 is a central component of SG formation by interacting with other SG proteins [93] . By its ability to bind ubiquitin, it promotes protein movement along microtubules. The viral protein transactivator of pX (Tax) compromises SGs formation mediated by HDAC6. In the nucleus, Tax is involved in spreading virus within cells. In addition, in the cytoplasm, Tax interacts with HDAC6 and inhibits SGs formation [94] .
Interferon (IFN) signaling is crucial for host cells to fight infections. Its expression is induced by IRF3 (interferon regulatory factor 3), which requires two co-activators, β-catenin and CBP, which are both activated by HDAC6-mediated deacetylation and PKC-β-mediated phosphorylation, respectively [95] . Moreover, PKC-α phosphorylates HDAC6 leading to increased deacetylase activity and enhanced HDAC6 nuclear translocation. To reinforce this mechanism, depletion of HDAC6, IRF-3 or PKC-α leads to decreased IFN expression and viral replication [96] .
The pathogenic potential of influenza A virus H5N1 strain could be due to induction of apoptosis in infected cells. Interestingly, HDAC6 is cleaved by caspase 3 in influenza A virus infected-cells, leading to removal of its BUZ domain. Then, exposure of the SE14 domain is responsible for the stabilization of HDAC6 cytoplasmic retention, thus promoting apoptosis induction. Furthermore, HDAC6 is involved in viral propagation through the regulation of microtubules and actin polymerization promoting protein trafficking and plasma membrane budding [97] .
In conclusion, through its ability to modulate microtubule architecture, HDAC6 enhances immune function under viral or bacterial infection; however, it can also contribute to viral propagation.
HDAC6 inhibitors
Although HDACi represent the most extensively investigated family of epigenetic modulators, most are pan-HDACi whereas only a few molecules are HDAC6-specific (Table 2 ; for review, see [54] ). Considering the implication of HDAC6 in cancer progression, Alzheimer's disease or rheumatoid arthritis, this isoenzyme became an interesting and important pharmacological target.
Discovery of specific HDAC6i was so far ineffective due to the absence of crystallization data especially covering the active sites of HDAC6 thus preventing a rational development of inhibitors. However, future science group Review Seidel, Schnekenburger, Dicato & Diederich a homology model using the crystal structure of HDAC8 allowed to demonstrate that tubastatin A targets specifically HDAC6 [98] . Moreover, the treatment of primary neural cells with this compound induces α-tubulin hyperacetylation without modulating histone H4, which is in agreement with the inhibition of cytoplasmic HDAC6.
Most HDAC6i were tested on various cancer cell lines and induced α-tubulin acetylation, exhibited antiproliferative activity and promoted cancer cell death [99] [100] [101] [102] [103] . In addition, some molecules were tested on mouse tumors where they decreased tumor size without affecting animal weight [102] .
The best-characterized HDAC6i is the hydroxamate tubacin. This molecule induces α-tubulin acetylation associated with microtubule stabilization and decreased cell mobility [104] . HDAC6 inhibition by tubacin leads to increased Ku70 acetylation that releases and acti- ACY-775 7.5 [101] Aminoacid-containing hydroxamic acids 4n 1700 [103] Biarryl hydroxamic acids <0.2-16 [111] C-3 substitued vorinostat derivative 8000 [111] Chiral 3,4.dihydroquinoxalin-2(1H)-one 10-310 [112] 3, 4-dihydroquinoxalin-1(2H)-one derivatives 40-310 [111] HPOB 6 56 [102] Nexturastat A 5 [99] Rocilinostat (ACY-1215) 4.7 [108] ST80 910 [100] Substitued phenylalanine-and pyridylalanine-based 1700-4000 [111] Tetrahydrocarboline derivatives 0.8-4.9 [111] Tetrahydro-1H-benzazepines 59-490 [113] Tetrahydroisoquinolines and isoindolines 36-89 [113] Tetrahydrothienol (2, 3-c)pyridines 20-35 [113] Tetrahydrothienol (3, 2-c)pyridines 24-47 [113] 1, 2, 3-Triazoles 1.9-7.3 [111] Tubacin 4 [104] Tubastatin A 15 [98] Triazolylphenyl 1.9-9.6 [114] Compounds containing a phenylisoxazole as a cap group 0.002-72.2 [115] Piperazine-2,5-dione aryl hydroxamates 110-170 [112] Benzamides 4-(acylaminomethyl)-N-hydrobenzamide 1a 19 [113] Others Compound bearing trifluoromethyl ketone ZBGs 70-89 [111] Compound containing a cycohephyl cap group and thiol ZBG 23 [111] Isoxazole derivatives 260-280 [111] Menadione 25300 [116] NQN-1 5540 [116] NQN-2 15600 [116] Quinazolin-4-one derivatives 8-1920 [117] ST3595 100 [118] ACY: Synthetic pyrimidine hydroxyl amide; HPOB: synthetic hydroxamate; NQN: synthetic naphthoquinone; ZBG: Zinc-binding group.
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Combining tubacin with other chemotherapeutic agents, such as doxorubicin, bortezomib (a proteasome inhibitor) or 17-AAG (an inhibitor of HSP90), enhances the inhibition of proliferation and viability of cancer cell lines [37, 105, 106] . Although the data obtained with tubacin are promising, high lipophilicity and tedious synthesis of this compound so far only allowed fundamental research rather than clinical investigations. Therefore, tubastatin A, a tubacin derivative, was synthetized [98] . Tubastatin A induces apoptosis and suppresses lymphoma cell colony formation [17] . In addition, tubastatin A protects neurons against oxidative stress is comparison with pan-HDAC inhibitors such as trichostatin A [98] . Therefore, this compound seems promising as an anticancer drug as well as for neuroprotection. However, in comparison with other HDAC6i such as ACY-738 and ACY-775, brain bioavailability of tubastatin A is reduced [101] .
Noteworthy, among HDAC6 inhibitors, only the hydroxamic acid-based compound ACY-1215 (Rocilinostat) is currently evaluated in clinical trials [119] . In cellulo studies using ACY-1215 against multiple myeloma cell lines indicate that this molecule induces α-tubulin acetylation, as well as cell death by apoptosis [107] . It has been shown that combination of an HDAC6 inhibitor with a proteasome inhibitor synergized their toxicity against cancer cells, including multiple myeloma, through impairment of proteasome-dependent and independent protein degradation [105] . Accordingly, a preclinical study with a multiple myeloma mouse model was conducted using ACY-1215 in combination with the proteasome inhibitor bortezomib [108] . Promising results indicated that this combination delays tumor growth and increases mouse survival accompanied with increased α-tubulin acetylation. Clinical trials are also conducted by Acetylon Pharmaceuticals, Inc. in patients with relapsed or refractory multiple myeloma using ACY-1215 alone or in combinatory treatments [120] . To date, one clinical study is completed concerning bioavailability of ACY-1215 in healthy subjects and the effect of food absorption on its pharmacokinetics. Several Phases I/II clinical studies are still in course; however, intermediary results exhibit promising effects of ACY-1215 in particular in combination with proteasome inhibitors [120] . Indeed, combination of ACY-1215 with both bortezomib (Velcade ® ) and dexamethasone results in clinical benefits in more than half of the treated patients with in most cases low-grade adverse events. However, some patients presented grade 3 or higher adverse events and regrettably one fatal adverse event occurred out of a cohort of 28 patients. Mechanistic analyses showed that α-tubulin acetylation was increased in all patients without impacting histone acetylation, which is in agreement with a specific inhibition of HDAC6 activity [120] . Combination of ACY-1215 with a standard treatment, lenalidomide (Revlimib ® ) and dexamethasone, in 22 patients suffering from multiple myeloma induces low-grade adverse events not related to ACY-1215 and grade 3 adverse events in three patients that could be related to ACY-1215 [120] . Despite these events, more than half of patients presented clinical benefits comprising one complete response, five very good partial responses, eight partial responses and three minor responses. An additional clinical study is in course with lymphoma patients were a combination of ACY-1215 with bortezomib exhibits synergistic apoptosis-inducing effects. Furthermore, bortezomib increases the pharmacodynamics and pharmacokinetic properties of ACY-1215 [120] .
Conclusion & future perspective
HDAC6 plays crucial roles in the development of numerous diseases, including the most lethal ones: cancer (eight million deaths each year), autoimmune diseases (third cause of death), HIV (three million deaths each year) and neurodegenerative diseases (6.2 million deaths each year).
Despite improved knowledge about HDAC6 function, many aspects remain unexplored: How do SE14 repeated sequences contribute to cytoplasmic retention of HDAC6? Which is the crystal structure of HDAC6 catalytic domains? The comprehension of these and other mechanisms could lead to rational HDAC6i synthesis. Indeed, some potent inhibitors were identified; however, their tedious synthesis or low bioavailability are problematic for efficient clinical investigations.
Consequently, it is necessary to develop new molecules able to target and modulate HDAC6 depending on the pathological situation. HDAC6 activity is required to prevent progression of selected cancer subtypes, Parkinson's and Huntington's disease, HIV infection and other viral or bacterial infections. However, HDAC6 inhibition seems required in other cancer types, Alzheimer's disease, RA, autoimmune disorders and viral replication.
Therefore, comprehension and knowledge about both expression profile and specific involvement of HDAC6 in a particular disease setting is indispensable for future use in personalized therapies. No writing assistance was utilized in the production of this manuscript.
Executive summary
• HDAC6 is the only HDAC isoenzyme with two functional catalytic domains.
• HDAC6 is mainly localized in the cytoplasm with specific physiological roles.
• HDAC6 deacetylates α-tubulin and cortactin involved in cytoskeleton structure and dynamics. Modulation of cytoskeleton architecture controls protein trafficking, cell movement or endocytosis.
• HDAC6 controls protein degradation by proteasome or through autophagy clearance. In addition, HDAC6
contributes to autophagic or apoptotic cell death induction.
• HDAC6 has a dual activity in several diseases. Indeed, it can play a role as tumor inducer or tumor suppressor depending on cancer type and stage. In neurodegenerative diseases, HDAC6 plays a protective role in Parkinson's and Huntington's diseases whereas its activity is an interesting target in Alzheimer's disease. HDAC6 not only co-regulates viral replication but also inhibits viral infection depending on the virus. • HDAC6 represents a potential therapeutic target for novel and specific inhibitors.
• Provides great clues about the molecular mechanisms of a direct implication of HDAC6 deacetylase activity in apoptotic cell death. 
